Jaguar Health, Inc.

NASDAQ: JAGXHealthcare / Biotechnology / USA
5.21-0.4100-7.30%Vol 457 7331Y Perf -95.38%
Jun 19th, 2019 16:00
BID5.20 ASK5.29
Open5.60 Previous Close5.62
Pre-Market5.15 After-Trading5.25
 -0.06 -1.15%  0.04 0.77%
Target Price
69.93 
Analyst Rating
Moderate Buy 2.00
Potencial %
1 242.23 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12M
-/-/100 
Value Ranking
 —    -
Insiders Value % 3/6/12M
-/-/100 
Growth Ranking
★+     38.85
Insiders Shares Cnt. % 3/6/12M
-/-/100 
Income Ranking
 —    -
Market Cap (mil)8 
Earnings Rating
Strong Sell
Price Range Ratio 52wk %
0.04 
Earnings Date
12th Aug 2019

Today's Price Range

5.155.70

52wk Range

5.15175.00

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Month
2 642.11%
3 Months
1 528.13%
6 Months
2 268.18%
1 Year
-95.38%
3 Years
-83.92%
5 Years
-

Name / TickerPriceChg.Chg.%
JAGX5.21-0.4100-7.30
AAPL197.87-0.5800-0.29
GOOG1 102.33-1.2700-0.12
MSFT135.690.53000.39
XOM75.32-0.4200-0.55
WFC45.65-0.4500-0.98
JNJ140.450.22000.16
FB187.48-0.9900-0.53
GE10.33-0.0900-0.86
JPM109.91-0.8000-0.72
Earnings HistoryEstimateReportedSurprise %
Q01 2019-13.29-12.595.27
Q03 2017-0.13-
Q02 2017-0.22-0.1245.45
Q01 2017--0.28-
Q03 2016-0.40-0.3025.00
Q02 2016-0.42-0.3516.67
Q01 2016-0.49-0.4312.24
Q03 2015-0.49-0.3626.53
Earnings Per EndEstimateRevision %Trend
6/2019 QR-7.40-158.74Negative
9/2019 QR-6.36-344.76Negative
12/2019 FY-34.63-304.08Negative
12/2020 FY-6.06--
Next Report Date12th Aug 2019
Estimated EPS Next Report-7.40
Estimates Count2
EPS Growth Next 5 Years %-
Volume Overview
Volume457 733
Shares Outstanding (in ths.)1 525
Trades Count1 358
Dollar Volume2 067 628
Avg. Volume183 134
Avg. Weekly Volume472 889
Avg. Monthly Volume696 412
Avg. Quarterly Volume301 164
Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
1 (50.00 %)
2 (100.00 %)
1 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
1 (50.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
RatingModerate Buy
2.00
Strong Buy
1.00
Strong Buy
1.00

Jaguar Health, Inc.

Jaguar Health Inc is a commercial stage pharmaceuticals company focused on developing novel, sustainably derived gastrointestinal products. The company's wholly-owned subsidiary, Napo Pharmaceuticals, Inc focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the marketplace from plants used traditionally in rainforest areas. It operates into two business segments namely Humal health and animal health. Its Mytesi (crofelemer) product is approved by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.

CEO: Lisa A Conte

Teplephone: +1 415 371-8300

Address: 201 Mission Street, San Francisco 94105, CA, USA

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

33%67%

Bearish Bullish

63%37%

Bearish Bullish

51%49%

News